Meeting
2018 ASCO Annual Meeting
A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax‑TF‑ADC) in previously treated, recurrent or metastatic cervical cancer.
Authors
Robert L. Coleman
The University of Texas MD Anderson Cancer Center, Houston, TX
Robert L. Coleman , Nicole Concin , Thomas J. Herzog , Linn Lena Woelber , Mansoor Raza Mirza , Bradley J. Monk , David Cibula , Domenica Lorusso , Antonio González-Martín , Kristian Windfeld , Jeroen Lammerts van Bueren , Signe Diness Vindeloev , Reshma A. Rangwala , Ignace Vergote
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5601)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5601
Abstract #
TPS5601
Poster Bd #
327b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
First Author: Lingying Wu
Poster
2020 ASCO Virtual Scientific Program
Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).
First Author: Ignace Vergote
Poster
2012 ASCO Annual Meeting
Phase II trial of everolimus in patients with previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
First Author: Prakash Varadarajan
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of exposure to clinical trials and standard-of-care therapy in metastatic or recurrent prostate cancer: An update.
First Author: Grace G Kim